Active Ingredient History
Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Astrocytoma (Phase 1)
Bile Duct Neoplasms (Phase 2)
Breast Neoplasms (Phase 1)
Burkitt Lymphoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Head and Neck Neoplasms (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
Kidney Diseases (Phase 1/Phase 2)
Kidney Neoplasms (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, Primary Effusion (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphomatoid Granulomatosis (Phase 2)
Melanoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1/Phase 2)
Neoplasms by Histologic Type (Phase 1/Phase 2)
Oligodendroglioma (Phase 1)
Ovarian Neoplasms (Phase 2)
Plasmablastic Lymphoma (Phase 2)
Prostatic Neoplasms (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Ulcer (Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Urogenital Neoplasms (Phase 1/Phase 2)
Urologic Diseases (Phase 1/Phase 2)
Urologic Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue